Olaparib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms, Triple-Negative
Conditions
Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female, Radiotherapy Side Effect
Trial Timeline
Jul 24, 2017 → Nov 29, 2021
NCT ID
NCT03109080About Olaparib
Olaparib is a phase 1 stage product being developed by AstraZeneca for Breast Neoplasms, Triple-Negative. The current trial status is completed. This product is registered under clinical trial identifier NCT03109080. Target conditions include Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female, Radiotherapy Side Effect.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03063710 | Pre-clinical | Completed |
| NCT05501548 | Phase 2 | Terminated |
| NCT04951492 | Phase 2 | Terminated |
| NCT05482074 | Phase 2 | Withdrawn |
| NCT05262608 | Phase 2 | UNKNOWN |
| NCT04884360 | Phase 3 | Active |
| NCT04515836 | Phase 2 | Recruiting |
| NCT04532645 | Pre-clinical | Completed |
| NCT04421963 | Phase 3 | Active |
| NCT04330040 | Approved | Completed |
| NCT04236414 | Phase 1 | Completed |
| NCT03782818 | Phase 1/2 | Terminated |
| NCT03829345 | Phase 2 | UNKNOWN |
| NCT03786796 | Phase 2 | Recruiting |
| NCT03955640 | Phase 1 | Terminated |
| NCT03742895 | Phase 2 | Active |
| NCT04152941 | Pre-clinical | Completed |
| NCT03570476 | Phase 2 | Terminated |
| NCT03470805 | Phase 2 | Completed |
| NCT03448718 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Neoplasms, Triple-Negative